Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Fernando Cristobal Diaz"'
Autor:
Khalid El Bairi, Salma Najem, Arman Reza Chowdhury, Abeid Omar, Omar Abdihamid, Laure-Anne Teuwen, Nada Benhima, Ainhoa Madariaga, Safa Elkefi, Fernando Cristobal Diaz, Sadaqat Hussain, Kristina Jenei, Nazik Hammad, Miriam Mutebi, Fidel Rubagumya, Dario Trapani, Nadia El Kadmiri, Nasser Laouali, Maryam Fourtassi
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEConflicts of interest (COIs) between oncologists and industry might considerably influence how the presentation of the research results is delivered, ultimately affecting clinical decisions and policy-making. Although there are many regulation
Externí odkaz:
https://doaj.org/article/600c0035a7f0432fbc390511f43401e2
Autor:
Michael Machiorlatti, Candace Robledo, Henry Kwang, Nabeel Sarhill, Fernando Cristobal Diaz, Elva Nora Osuna-Salazar
Publikováno v:
Cancer Research. 80:P6-11
Background: Breast cancer is the leading cause of cancer death in Hispanic women. Compared to non-Hispanic Whites, Hispanic women are more likely to be diagnosed at later stages, with larger tumors and more likely to die from their cancer. The health
Autor:
Dailis Barbara Corria Cedeno, Dave Patel, Michael LaPelusa, Hansapani Rodrigo, Fernando Cristobal Diaz, Ismael Polo Perez
Publikováno v:
Journal of Clinical Oncology. 38:11039-11039
11039 Background: Online health information is a central part of how patients learn about a cancer diagnosis. Involving patients in shared decision making is associated with better outcomes. Previous studies have identified a lack of high-quality, re
Autor:
Fernando Cristobal Diaz, Aurora O'Brate, Rubén M. Buey, Paraskevi Giannakakou, Shala L. Thomas, Jun Zhou, Fadlo R. Khuri, José Manuel Andreu, Adam I. Marcus
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
9 páginas, 5 figuras -- PAGS nros. 8838-8846
The combination of farnesyltransferase inhibitors (FTIs) and taxanes has been shown to result in potent antiproliferative and antimitotic synergy. Recent phase I and II clinical trials have shown tha
The combination of farnesyltransferase inhibitors (FTIs) and taxanes has been shown to result in potent antiproliferative and antimitotic synergy. Recent phase I and II clinical trials have shown tha